Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions

Pharmacogenomics Journal

Volumn 15, Issue 6, 2015, Pages 473-487

  Arimany Nardi, C ^a   Koepsell, H ^b   Pastor Anglada, M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMITRIPTYLINE; BENDAMUSTINE; DEBRISOQUINE; EFAVIRENZ; IMATINIB; LAMIVUDINE; METFORMIN; MORPHINE; O NORTRAMADOL; ORGANIC CATION TRANSPORTER 1; RALTEGRAVIR; SORAFENIB; TROPISETRON; VERAPAMIL; ZEBULARINE; ZIDOVUDINE; DRUG;

ANTIVIRAL THERAPY; ARTICLE; CANCER THERAPY; DIABETES MELLITUS; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG INHIBITION; DRUG RESPONSE; DRUG TRANSPORT; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; NONHUMAN; OVARY POLYCYSTIC DISEASE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; SLC22A1 GENE; ANIMAL; DRUG INTERACTION; GENETICS; METABOLISM; PHARMACOGENETICS; PROCEDURES;

ANIMALS; DRUG INTERACTIONS; HUMANS; ORGANIC CATION TRANSPORTER 1; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84947495814     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.78     Document Type: Article

References (102)

1. Volk C, Gorboulev V, Kotzsch A, Muller TD, Koepsell H. Five amino acids in the innermost cavity of the substrate binding cleft of organic cation transporter 1 interact with extracellular and intracellular corticosterone. Mol Pharmacol 2009; 76: 275-289
2. Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 2011; 201: 105-167
3. Koepsell H. The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 2013; 34: 413-435
4. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 1994; 372: 549-552
5. Schweifer N, Barlow DP. The Lx1 gene maps to mouse chromosome 17 and codes for a protein that is homologous to glucose and polyspecific transmembrane transporters. Mamm Genome 1996; 7: 735-740
6. Terashita S, Dresser MJ, Zhang L, Gray AT, Yost SC, Giacomini KM. Molecular cloning and functional expression of a rabbit renal organic cation transporter. Biochim Biophys Acta 1998; 1369: 1-6
7. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 1997; 51: 913-921
8. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 1997; 16: 871-881
9. Hayer M, Bonisch H, Bruss M. Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1). Ann Hum Genet 1999; 63: 473-482
10. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007; 24: 1227-1251
11. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009; 50: 1227-1240
12. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009; 86: 299-306
13. Han TK, Everett RS, Proctor WR, Ng CM, Costales CL, Brouwer KL et al. Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. Mol Pharmacol 2013; 84: 182-189
14. Gilchrist SE, Alcorn J. Lactation stage-dependent expression of transporters in rat whole mammary gland and primary mammary epithelial organoids. Fundam Clin Pharmacol 2010; 24: 205-214
15. Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N et al. Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. J Pharmacol Exp Ther 2008; 324: 558-567
16. Moreno-Navarrete JM, Ortega FJ, Rodriguez-Hermosa JI, Sabater M, Pardo G, Ricart W et al. OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes 2011; 60: 168-176
17. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 2005; 20: 452-477
18. Zhang H, Massey D, Tremelling M, Parkes M. Genetics of inflammatory bowel disease: clues to pathogenesis. Br Med Bull 2008; 87: 17-30
19. Lin CJ, Tai Y, Huang MT, Tsai YF, Hsu HJ, Tzen KY et al. Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. J Neurochem 2010; 114: 717-727
20. Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 2004; 308: 2-9
21. Gupta S, Wulf G, Henjakovic M, Koepsell H, Burckhardt G, Hagos Y. Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel. J Pharmacol Exp Ther 2011; 341: 16-23
22. More SS, Li S, Yee SW, Chen L, Xu Z, Jablons DM et al. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther 2010; 9: 1058-1069
23. Schaeffeler E, Hellerbrand C, Nies AT, Winter S, Kruck S, Hofmann U et al. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med 2011; 3: 82
24. Martinez-Becerra P, Vaquero J, Romero MR, Lozano E, Anadon C, Macias RI et al. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Mol Pharm 2012; 9: 1693-1704
25. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236
26. Tachampa K, Takeda M, Khamdang S, Noshiro-Kofuji R, Tsuda M, Jariyawat S et al. Interactions of organic anion transporters and organic cation transporters with mycotoxins. J Pharmacol Sci 2008; 106: 435-443
27. Winter TN, Elmquist WF, Fairbanks CA. OCT2 and MATE1 provide bidirectional agmatine transport. Mol Pharm 2011; 8: 133-142
28. Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA et al. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci USA 2014; 111: 9983-9988
29. Lovejoy KS, Todd RC, Zhang S, McCormick MS, D'Aquino JA, Reardon JT et al. cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc Natl Acad Sci USA 2008; 105: 8902-8907
30. Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P et al. Transport of lamivudine [(-)-beta-L-2', 3'-dideoxy-3'-thiacytidine] and high-Affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 2009; 329: 252-261
31. Arimany-Nardi C, Montraveta A, Lee-Verges E, Puente XS, Koepsell H, Campo E et al. Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells. Pharmacogenomics J 2015; 15: 363-371
32. Nies AT, Schwab M. Organic cation transporter pharmacogenomics and drugdrug interaction. Expert Rev Clin Pharmacol 2010; 3: 707-711
33. Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002; 12: 591-595
34. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273-280
35. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422-1431
36. Christensen MM, Pedersen RS, Stage TB, Brasch-Andersen C, Nielsen F, Damkier P et al. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics 2013; 23: 526-534
37. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009; 9: 242-247
38. Umamaheswaran G, Praveen RG, Damodaran SE, Das AK, Adithan C. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Clin Exp Med 2015 (in press).
39. Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010; 59: 2672-2681
40. Tkac I, Klimcakova L, Javorsky M, Fabianova M, Schroner Z, Hermanova H et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab 2013; 15: 189-191
41. Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011; 21: 837-850
42. Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ et al. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 2011; 90: 674-684
43. Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G et al. Reducedfunction SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 2009; 58: 1434-1439
44. Tarasova L, Kalnina I, Geldnere K, Bumbure A, Ritenberga R, Nikitina-Zake L et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genomics 2012; 22: 659-666
45. Gambineri A, Tomassoni F, Gasparini DI, Di Rocco A, Mantovani V, Pagotto U et al. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95: E204-E208
46. Chen L, Takizawa M, Chen E, Schlessinger A, Segenthelar J, Choi JH et al. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther 2010; 335: 42-50
47. Yoon H, Cho HY, Yoo HD, Kim SM, Lee YB. Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects. AAPS J 2013; 15: 571-580
48. Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 2007; 52: 117-122
49. Jung N, Lehmann C, Rubbert A, Schomig E, Fatkenheuer G, Hartmann P et al. Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients. Infection 2013; 41: 379-385
50. Choi MK, Song IS. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm Drug Dispos 2012; 33: 170-178
51. Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM et al. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology 2013; 58: 1065-1073
52. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009; 15: 6062-6069
53. Arimany-Nardi C, Errasti-Murugarren E, Minuesa G, Martinez-Picado J, Gorboulev V, Koepsell H et al. Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors. Br J Pharmacol 2014; 171: 3868-3880
54. Minematsu T, Giacomini KM. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 2011; 10: 531-539
55. Nies AT, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M et al. Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res 2014; 20: 985-994
56. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood 2005; 106: 1133-1134
57. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258-264
58. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697-704
59. Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009; 15: 4750-4758
60. Gromicho M, Magalhaes M, Torres F, Dinis J, Fernandes AR, Rendeiro P et al. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Oncol Rep 2013; 29: 741-750
61. Zach O, Krieger O, Foedermayr M, Zellhofer B, Lutz D. OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients. Leuk Lymphoma 2008; 49: 2222-2223
62. White DL, Saunders VA, Dang P, Engler J, Hughes TP. OCT-1 activity measurement provides a superior imatinib response predictor than screening for singlenucleotide polymorphisms of OCT-1. Leukemia 2010; 24: 1962-1965
63. Maffioli M, Camos M, Gaya A, Hernandez-Boluda JC, Alvarez-Larran A, Domingo A et al. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res 2011; 35: 1014-1019
64. Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC et al. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 2010; 24: 1243-1245
65. Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, Tagawa H et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 2010; 55: 731-737
66. Singh O, Chan JY, Lin K, Heng CC, Chowbay B. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. PLoS One 2012; 7: e51771
67. Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS et al. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol 2013; 24: 756-760
68. Nambu T, Hamada A, Nakashima R, Yuki M, Kawaguchi T, Mitsuya H et al. Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia. Biol Pharm Bull 2011; 34: 114-119
69. Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T et al. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit 2011; 33: 244-250
70. Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 2013; 98: 193-200
71. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008; 112: 3348-3354
72. Tzvetkov MV, Saadatmand AR, Lotsch J, Tegeder I, Stingl JC, Brockmoller J. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther 2011; 90: 143-150
73. Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmoller J. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol 2013; 86: 666-678
74. Fukuda T, Chidambaran V, Mizuno T, Venkatasubramanian R, Ngamprasertwong P, Olbrecht V et al. OCT1 genetic variants influence the pharmacokinetics of morphine in children. Pharmacogenomics 2013; 14: 1141-1151
75. Saadatmand AR, Tadjerpisheh S, Brockmoller J, Tzvetkov MV. The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem Pharmacol 2013; 83: 1427-1434
76. Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmoller J. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J 2012; 12: 22-29
77. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics 2011; 12: 79-82
78. Dos Santos Pereira JN, Tadjerpisheh S, Abu Abed M, Saadatmand AR, Weksler B, Romero IA et al. The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family. AAPS J 2014; 16: 1247-1258
79. Ahlin G, Chen L, Lazorova L, Chen Y, Ianculescu AG, Davis RL et al. Genotypedependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J 2011; 11: 400-411
80. Ohishi Y, Nakamuta M, Ishikawa N, Saitoh O, Nakamura H, Aiba Y et al. Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol 2014; 49: 332-342
81. O'Brien VP, Bokelmann K, Ramirez J, Jobst K, Ratain MJ, Brockmoller J et al. Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene. J Pharmacol Exp Ther 2013; 347: 181-192
82. Rulcova A, Krausova L, Smutny T, Vrzal R, Dvorak Z, Jover R et al. Glucocorticoid receptor regulates organic cation transporter 1 (OCT1, SLC22A1) expression via HNF4alpha upregulation in primary human hepatocytes. Pharmacol Rep 2013; 65: 1322-1335
83. Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R et al. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 2014; 96: 370-379
84. Grube M, Ameling S, Noutsias M, Kock K, Triebel I, Bonitz K et al. Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am J Pathol 2011; 178: 2547-2559
85. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006; 36: 963-988
86. Salomon JJ, Muchitsch VE, Gausterer JC, Schwagerus E, Huwer H, Daum N et al. The cell line NCl-H441 is a useful in vitro model for transport studies of human distal lung epithelial barrier. Mol Pharm 2014; 11: 995-1006
87. Zhang T, Xiang CD, Gale D, Carreiro S, Wu EY, Zhang EY. Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition. Drug Metab Dispos 2008; 36: 1300-1307
88. Bottalico B, Larsson I, Brodszki J, Hernandez-Andrade E, Casslen B, Marsal K et al. Norepinephrine transporter (NET), serotonin transporter (SERT), vesicular monoamine transporter (VMAT2) and organic cation transporters (OCT1, 2 and EMT) in human placenta from pre-eclamptic and normotensive pregnancies. Placenta 2004; 25: 518-529
89. Augustine LM, Markelewicz RJ Jr, Boekelheide K, Cherrington NJ. Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier. Drug Metab Dispos 2005; 33: 182-189
90. Bexten M, Oswald S, Grube M, Jia J, Graf T, Zimmermann U et al. Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm 2015; 12: 171-178
91. Dickens D, Owen A, Alfirevic A, Giannoudis A, Davies A, Weksler B et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol 2012; 83: 805-814
92. Hosotani R, Chowdhury P, McKay D, Rayford PL. Effect of L364718, a new CCK antagonist, on amylase secretion in isolated rat pancreatic acini. Pancreas 1988; 3: 95-98
93. Muller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 2005; 70: 1851-1860
94. Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003; 100: 5902-5907
95. Kang HJ, Song IS, Shin HJ, Kim WY, Lee CH, Shim JC et al. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos 2007; 35: 667-675
96. Giannoudis A, Wang L, Jorgensen AL, Xinarianos G, Davies A, Pushpakom S et al. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 2013; 121: 628-637
97. Grinfeld J, Gerrard G, Alikian M, Alonso-Dominguez J, Ale S, Valganon M et al. A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. Br J Haematol 2013; 163: 631-639
98. Di Paolo A, Polillo M, Capecchi M, Cervetti G, Barate C, Angelini S et al. The c.480C4G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics J 2014; 14: 328-335
99. Jacobs C, Pearce B, Du Plessis M, Hoosain N, Benjeddou M. Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa. Genet Mol Biol 2014; 37: 350-359
100. Du Plessis M, Pearce B, Jacobs C, Hoosain N, Benjeddou M. Genetic polymorphisms of the organic cation transporter 1 gene (SLC22A1) within the Cape Admixed population of South Africa. Mol Biol Rep 2014; 42: 665-672
101. Itoda M, Saito Y, Maekawa K, Hichiya H, Komamura K, Kamakura S et al. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab Pharmacokinet 2004; 19: 308-312
102. Umamaheswaran G, Praveen RG, Arunkumar AS, Das AK, Shewade DG, Adithan C. Genetic analysis of OCT1 gene polymorphisms in an Indian population. Indian J Hum Genet 2011; 17: 164-168.